Leerink Partnrs Decreases Earnings Estimates for AC Immune

AC Immune SA (NASDAQ:ACIU) – Leerink Partnrs dropped their FY2027 earnings estimates for AC Immune in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.06 per share for the year, down from their prior estimate of $0.12. The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $91.60 million.

Several other equities research analysts have also recently weighed in on the stock. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Wednesday.

AC Immune Stock Performance

NASDAQ:ACIU opened at $3.09 on Thursday. AC Immune has a fifty-two week low of $2.25 and a fifty-two week high of $5.14. The company has a market cap of $305.72 million, a price-to-earnings ratio of -4.29 and a beta of 1.28. The stock has a fifty day moving average price of $3.27 and a 200-day moving average price of $3.45.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new stake in AC Immune in the first quarter valued at about $30,000. BNP Paribas Financial Markets boosted its stake in shares of AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares in the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of AC Immune in the 2nd quarter valued at approximately $40,000. Vanguard Capital Wealth Advisors acquired a new position in AC Immune during the 2nd quarter worth approximately $56,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.